Who benefits from a defibrillator?

September 03, 2019

Implantable defibrillators can save lives, but also harbor risks. A major European study headed by three researchers from the Technical University of Munich (TUM), LMU München and University Medical Center Göttingen has found that a special ECG method can help to identify the patients most likely to benefit from these devices. The results of the study have now been published in The Lancet.

In heart patients with potentially life-threatening arrhythmias, a strong electrical shock applied to the cardiac muscle can reset the heart to its regular rhythm. This is precisely the task of defibrillators, which are inserted into the chest like pacemakers. Under current guidelines, physicians implant these devices as a preventive measure in patients with certain heart conditions. The procedure is performed more than 100,000 times per year in the EU. Apart from the high costs for the health care system, the devices also pose a risk: According to estimates, one in four implanted defibrillators will lead to significant complications within ten years - from infections to spontaneous electric shocks.

The EU-CERT-ICD study therefore examined the benefits of prophylactically implanted defibrillators throughout Europe. In a sub-study of the EU-CERT-ICD project, the scientists led by first author Prof. Axel Bauer (formerly LMU and currently Medical University of Innsbruck) and the two co-senior authors Prof. Georg Schmidt (TUM) and Prof. Markus Zabel (University Medical Center Göttingen) wanted to identify the patients who benefit most from the operation.

PRD: an indicator of the electrical instability of the heart

Each heartbeat consists of a sequence of excitation (depolarization) and regression of excitation (repolarization). Heart failure often leads to overactivity of the sympathetic nervous system, a part of the autonomic nervous system that is active in stressful situations. This overactivity can destabilize the repolarization of the heart, resulting in a dramatic increase in the risk of damaging arrhythmias. These dangerous instabilities in repolarization can be recognized using a relatively new ECG procedure known as periodic repolarization dynamics (PRD). "Although the procedure involves intelligent algorithms, the measurements are relatively simple," explains Axel Bauer, who worked with Georg Schmidt to develop and validate the method.

In their prospective study, the scientists tracked 1,371 patients who met the current criteria for the implant of a defibrillator. Of the group, 968 actually underwent the operation, while the doctors treating the other 403 patients decided against a defibrillator.

High PRD value: indicative of benefits from an implantable defibrillator

The preventive implantation of a defibrillator resulted in an overall 43 percent decrease in mortality over the subsequent four-year period. For patients with a PRD value greater than or equal to 7.5 degrees, the reduction in the mortality risk was significantly larger, at 75 percent. For PRD values below 7.5 degrees, the mortality risk was reduced by only 31 percent. "PRD could become an important decision making tool for physicians," says Georg Schmidt, the head of the Biosignal Processing Working Group at TUM's Klinikum rechts der Isar. "With the additional information, patients who would probably not benefit from a defibrillator could be spared the risk of an implant. Instead we could focus on those whose lives would likely be extended by the device." The results will first have to be confirmed in further studies, however, before they can be included in medical treatment guidelines. "An important step, among others, would be to conduct a study over a longer period," says Markus Zabel, the head of the main EU-CERT study.
-end-
Publication:

A. Bauer, M. Klemm, KD. Rizas, W. Hamm, L. v. Stülpnagel, M. Dommasch, A. Steger, A. Lubinski, P. Flevari, M. Harden, T. Friede, S. Kääb, B. Merkely, C. Sticherling, R. Willems, H. Huikuri, M. Malik, G. Schmidt, M. Zabel, and the EU-CERT-ICD investigators. "Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study ". The Lancet (2019). DOI: 10.1016/S0140-6736(19)31996-8

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31996-8/fulltext

More information:

For the EU-CERT-ICD study (European Comparative Effectiveness Research to Assess the Use of Primary Prophylactic Implantable Cardioverter Defibrillators), patients have been examined at 44 centers in 15 EU countries since 2014. The study was funded by the European Union.

Contact:

Prof. Dr. Georg Schmidt
Technical University of Munich
Klinikum rechts der Isar
Department of Internal Medicine I, Cardiology
Tel: +49 89 4140 7979
gschmidt@tum.de

Univ.-Prof. Dr. Axel Bauer
Medical University of Innsbruck
Director of University Hospital Internal Medicine III - Cardiology and Angiology
Tel. +43 512 504-25621
axel.bauer@i-med.ac.at

Prof. Dr. Markus Zabel
University Medical Center Göttingen
Head of Research Focus Clinical Electrophysiology
Tel. +49 551 3965255
markus.zabel@med.uni-goettingen.de

Technical University of Munich (TUM)

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by Lluís Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.